

Draft Guidance on Hydromorphone Hydrochloride

This draft guidance, once finalized, will represent the Food and Drug Administration's (FDA's) current thinking on this topic. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. You can use an alternative approach if the approach satisfies the requirements of the applicable statutes and regulations. If you want to discuss an alternative approach, contact the Office of Generic Drugs.

Active ingredient: Hydromorphone Hydrochloride

Form/Route: Tablet/Oral

Recommended study: 2 studies

1. Type of study: Fasting
Design: Single-dose, two-way crossover in-vivo
Strength: 8 mg
Subjects: Healthy males and nonpregnant females, general population
Additional comments: A clear plan for continuous respiratory monitoring from the time of dosing past the time of expected peak effect of the drug (i.e. at least 3 hours from dosing) should be included. Standard operating procedures (SOPs) should be in place for assessing and treating ventilatory depression, and personnel qualified to treat ventilatory emergencies should be immediately available.

2. Type of study: Fed
Design: Single-dose, two-way crossover in-vivo
Strength: 8 mg
Subjects: Healthy males and nonpregnant females, general population
Additional comments: Please see comments above.

Analytes to measure (in appropriate biological fluid): Hydromorphone in plasma

Bioequivalence based on (90% CI): Hydromorphone

Waiver request of in-vivo testing: 2 mg and 4 mg based on (i) acceptable bioequivalence studies on the 8 mg strength, (ii) acceptable in-vitro dissolution testing of all strengths, and (iii) proportional similarity of the formulations across all strengths.

Dissolution test method and sampling times:

Please note that a **Dissolution Methods Database** is available to the public at the OGD website at <http://www.accessdata.fda.gov/scripts/cder/dissolution/>. Please find the dissolution information for this product at this website. Please conduct comparative dissolution testing on 12 dosage units each of all strengths of the test and reference products. Specifications will be determined upon review of the application.